Literature DB >> 24760220

A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….

Ron Levy1.   

Abstract

This is a journey that began in medical school at Stanford in 1963 and that is still underway, now as faculty member here for the past 40 years. History is by its nature selective, and I chose highlights that reflect on the remarkable progress we have made using the immune system to treat cancer. We will never be satisfied until we eliminate suffering and early mortality from cancer, but the progress is indeed remarkable as are the people who have contributed to it.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760220     DOI: 10.1007/s12026-014-8506-3

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  15 in total

1.  The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies.

Authors:  R Levy; E Hurwitz; R Maron; R Arnon; M Sela
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

2.  The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.

Authors:  E Hurwitz; R Levy; R Maron; M Wilchek; R Arnon; M Sela
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

3.  The in vitro antibody response to cell surface antigens. II. Monoclonal antibodies to human leukemia cells.

Authors:  R Levy; J Dilley
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

4.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

5.  Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization.

Authors:  R Levy; J Dilley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

6.  CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Kipp Weiskopf; Ash A Alizadeh; Josh Brody; Antonia Müller; Russell Pachynski; Debra Czerwinski; Steven Coutre; Mark P Chao; Lieping Chen; Thomas F Tedder; Ronald Levy
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

7.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

Authors:  Joshua D Brody; Weiyun Z Ai; Debra K Czerwinski; James A Torchia; Mia Levy; Ranjana H Advani; Youn H Kim; Richard T Hoppe; Susan J Knox; Lewis K Shin; Irene Wapnir; Robert J Tibshirani; Ronald Levy
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

Authors:  L W Kwak; M J Campbell; D K Czerwinski; S Hart; R A Miller; R Levy
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

9.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

10.  The monoclonality of human B-cell lymphomas.

Authors:  R Levy; R Warnke; R F Dorfman; J Haimovich
Journal:  J Exp Med       Date:  1977-04-01       Impact factor: 14.307

View more
  1 in total

Review 1.  The early history of Stanford Immunology.

Authors:  Patricia P Jones; Leonore A Herzenberg
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.